Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC0-12 monitoring in cardiac transplant recipients over the first year post-transplantation

European Journal of Clinical Pharmacology

Volumn 58, Issue 12, 2003, Pages 813-820

  Monchaud, C ^a   Rousseau, A ^a,b   Leger, F ^a   David, O J ^c   Debord, J ^a   Dantoine, T ^a   Marquet, P ^a  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b UNIVERSITY OF LIMOGES   (France)

^c ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

Immunosuppressants; Therapeutic drug monitoring; Transplantation

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG MONITORING; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MULTIPLE REGRESSION; POPULATION MODEL; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; SAMPLING;

EID: 0037617685     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0559-5     Document Type: Article

References (23)

1. Oellerich M, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, Lindholm A, Halloran P, Gallicano K, Wonigeit K et al (1995) Lake Louise consensus document: Hawk's Cay meeting in organ transplantation: report of the consensus panel. Ther Drug Monit 17:642-654
2. Belitsky P, Dunn S, Jonhston A, Levy G (2000) Impact of absorption profiling on efficacy and safety of cyclosporin therapy in transplant recipients. Clin Pharmacokinet 39:117-125
3. Lindholm A, Kahan BD (1993) Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 54:205-218
4. Keown P, Kahan BD, Johnston A, Levy G, Dunn SP, Cittero F, Grino JM, Hoyer PF, Wolf P, Halloran PF (1998) Optimization of cyclosporine therapy with new therapeutic drug monitoring strategies: report from the international Neoral TDM advisory consensus meeting (Vancouver, November 1997). Transplant Proc 30:1645-1649
5. Dumont JR, Ensom MH (2000) Methods for clinical monitoring of cyclosporine in transplant patients. Clin Pharmacokinet 38:427-447
6. Cantarovich M, Elstein E, de Varennes B, Barkun JS (1999) Clinical benefit of Neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation 12:1839-1842
7. Armstrong VW, Oellerich M (2001) New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine. Clin Biochem 34:9-16
8. Belitsky P, Levy GA, Johnston A (2000) Neoral absorption profiling: an evolution in effectiveness. Transplant Proc 32:45S
9. Levy G (2001) C2 monitoring strategy for optimising cyclosporin immunosuppression from Neoral formulation. Biodrugs 15:279-290
10. Cooney GF, Johnston A (2001) Neoral C-2 monitoring in cardiac transplant patients. Transplant Proc 33:1572-1575
11. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R (1998) Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant 12:243-249
12. David O, Johnston A (2001) Limited sampling strategies for estimating cyclosporin area under the concentration-time curve: review of current algorithms. Ther Drug Monit 23:100-114
13. Lee KL, Lee KT, Chung HM, Lin YP (1998) Estimation of mean relative bioavailability of cyclosporine Sandimmune and Neoral using NONMEM, in renal transplant recipients. Transplant Proc 30:3526-3529
14. Leger F, Debord J, Le Meur Y, Rousseau A, Buchler M, Lachatre G, Paintaud G, Marquet P (2002) Maximum a posteriori Bayesian estimation of oral cyclosporine pharmacokinetics in stable renal transplant patients. Clin Pharmacokinet 41:71-80
15. Debord J, Risco E, Harel M, Le Meur Y, Buchler M, Lachatre G, Le Guellec C, Marquet P (2001) Gamma distribution of absorption times: application to oral cyclosporine. Clin Pharmacokinet 40:375-382
16. Cooney GF, Jeevanandam V, Choudhury S, Feutren G, Mueller EA, Eisen HJ (1998) Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year. Transplant Proc 30:1892-1894
17. Yee GC, McGuire TR (1990) Pharmacokinetic drug interactions with cyclosporin (Part II). Clin Pharmacokinet 19:319-332
18. D'Argenio DZ (1981) Optimal sampling times for pharmacokinetic experiments. J Pharmacokinet Biopharm 9:739-756
19. Sheiner LB, Beal SL (1981) Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 9:503-512
20. David O, Johnston A, Cooney G (1999) Sparse sample measurements of cyclosporine AUC after Neoral in heart transplant patients. Ther Drug Monit 21:447
21. Wacke R, Rohde B, Engel G, Kundt G, Hehl EM, Bast R, Seiter H, Drewelow B (2000) Comparison of several approaches of therapeutic drug monitoring of cyclosporin A based on individual pharmacokinetics. Eur J Clin Pharmacol 56:43-48
22. Mahalati K, Belitsky P, Sketris I, West K, Panek R (1999) Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 68:55-62
23. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Asperlet L, Metrakos P (1998) Comparison of Neoral dose monitoring with cyclosporine trough levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation 66:1621-1627